OTCMKTS:KHTRF

Knight Therapeutics Competitors

$4.21
0.00 (0.00 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.21
Now: $4.21
$4.21
50-Day Range
$3.95
MA: $4.18
$4.43
52-Week Range
$3.95
Now: $4.21
$5.69
VolumeN/A
Average Volume30,679 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Knight Therapeutics (OTCMKTS:KHTRF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying KHTRF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Knight Therapeutics, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Abacus Health Products (OTCMKTS:ABAHF) and Knight Therapeutics (OTCMKTS:KHTRF) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Abacus Health Products and Knight Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abacus Health Products0000N/A
Knight Therapeutics00303.00

Knight Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 90.02%. Given Knight Therapeutics' higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Abacus Health Products.

Earnings and Valuation

This table compares Abacus Health Products and Knight Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abacus Health ProductsN/AN/AN/AN/AN/A
Knight TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Abacus Health Products and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abacus Health ProductsN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Summary

Knight Therapeutics beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and Knight Therapeutics (OTCMKTS:KHTRF) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Earnings and Valuation

This table compares Acreage and Knight Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcreageN/AN/AN/AN/AN/A
Knight TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Acreage and Knight Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acreage01202.67
Knight Therapeutics00303.00

Acreage currently has a consensus target price of $8.4333, suggesting a potential upside of 204.45%. Knight Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 90.02%. Given Acreage's higher probable upside, equities analysts clearly believe Acreage is more favorable than Knight Therapeutics.

Profitability

This table compares Acreage and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcreageN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Summary

Knight Therapeutics beats Acreage on 2 of the 3 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Knight Therapeutics (OTCMKTS:KHTRF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares Applied Biosciences and Knight Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied BiosciencesN/AN/AN/AN/AN/A
Knight TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Applied Biosciences and Knight Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Biosciences0000N/A
Knight Therapeutics00303.00

Knight Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 90.02%. Given Knight Therapeutics' higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Applied Biosciences.

Profitability

This table compares Applied Biosciences and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied BiosciencesN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Summary

Knight Therapeutics beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Knight Therapeutics (OTCMKTS:KHTRF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares Ayr Strategies and Knight Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
Knight TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Ayr Strategies and Knight Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Knight Therapeutics00303.00

Ayr Strategies presently has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. Knight Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 90.02%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Ayr Strategies.

Profitability

This table compares Ayr Strategies and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Summary

Knight Therapeutics beats Ayr Strategies on 2 of the 3 factors compared between the two stocks.

Can B (NASDAQ:CANB) and Knight Therapeutics (OTCMKTS:KHTRF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Can B and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Can B and Knight Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
Knight TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Can B and Knight Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
Knight Therapeutics00303.00

Knight Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 90.02%. Given Knight Therapeutics' higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Can B.

Summary

Knight Therapeutics beats Can B on 2 of the 2 factors compared between the two stocks.

Cansortium (OTCMKTS:CNTMF) and Knight Therapeutics (OTCMKTS:KHTRF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Cansortium and Knight Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CansortiumN/AN/AN/A
Knight TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Cansortium and Knight Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CansortiumN/AN/AN/AN/AN/A
Knight TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Cansortium and Knight Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cansortium00103.00
Knight Therapeutics00303.00

Cansortium presently has a consensus target price of $1.20, suggesting a potential upside of 35.90%. Knight Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 90.02%. Given Knight Therapeutics' higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Cansortium.

Summary

Knight Therapeutics beats Cansortium on 2 of the 2 factors compared between the two stocks.


Knight Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84flat$0.00N/A0.00Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77flat$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.40flat$0.00N/A0.00Increase in Short Interest
Gap Up
AYRSF
Ayr Strategies
1.4$21.26flat$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.52flat$0.00N/A0.00Gap Down
Cansortium logo
CNTMF
Cansortium
1.1$0.88flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.18flat$0.00N/A0.00News Coverage
Gap Up
Choom logo
CHOOF
Choom
0.5$0.09flat$0.00N/A0.00Decrease in Short Interest
Gap Down
CPHRF
Cipher Pharmaceuticals
1.2$1.06flat$0.00N/A0.00Decrease in Short Interest
Gap Down
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.24flat$0.00N/A0.00Gap Up
Cosmos logo
COSM
Cosmos
0.5$5.75flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Cresco Labs logo
CRLBF
Cresco Labs
1.5$12.12flat$0.00N/A0.00News Coverage
Curaleaf logo
CURLF
Curaleaf
1.6$14.36flat$0.00N/A0.00Gap Up
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00flat$0.00N/A0.00Decrease in Short Interest
Gap Down
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.15flat$0.00N/A0.00Increase in Short Interest
Gap Down
EVIO logo
EVIO
EVIO
0.6$0.00flat$0.00N/A0.00Increase in Short Interest
Gap Up
Flower One logo
FLOOF
Flower One
0.4$0.26flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05flat$0.00N/A0.00Decrease in Short Interest
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01flat$0.00N/A0.00
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$29.49flat$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.62flat$0.00N/A0.00Increase in Short Interest
Gap Down
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.80flat$0.00N/A0.00Gap Up
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01flat$0.00N/A0.00Decrease in Short Interest
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.68flat$0.00N/A0.00News Coverage
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.22flat$0.00N/A0.00Gap Down
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.32flat$0.00N/A0.00Decrease in Short Interest
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.05flat$0.00N/A0.00Gap Up
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.43flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01flat$0.00N/A0.00Increase in Short Interest
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.05flat$0.00N/A0.00
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.38flat$0.00N/A0.00Increase in Short Interest
Gap Up
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.32flat$0.00N/A0.00Increase in Short Interest
Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.33flat$0.00N/A0.00Increase in Short Interest
MJardin Group logo
MJARF
MJardin Group
1.1$0.07flat$0.00N/A0.00Increase in Short Interest
Gap Up
MYHI
Mountain High Acquisitions
0.5$0.02flat$0.00N/A0.00Decrease in Short Interest
Gap Up
PHCEF
Pharmacielo
0.7$1.23flat$0.00N/A0.00News Coverage
Plus Products logo
PLPRF
Plus Products
1.1$0.55flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00flat$0.00N/A0.00
PCYN
Procyon
0.4$0.60flat$0.00N/A0.00Gap Up
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01flat$0.00N/A0.00Decrease in Short Interest
SANP
Santo Mining
0.5$0.01flat$0.00N/A0.00News Coverage
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.23flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40flat$0.00N/A0.00
TerrAscend logo
TRSSF
TerrAscend
1.7$10.58flat$0.00N/A0.00Increase in Short Interest
Gap Up
The Flowr logo
FLWPF
The Flowr
1.5$0.25flat$0.00N/A0.00Decrease in Short Interest
Gap Up
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.0$0.31flat$0.00N/A0.00Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.